HIGHLIGHTS
- who: Ji Ma and collaborators from the Shizuoka Cancer Center, Japan Kyoto University, Japan have published the article: Efficacy and safety of anti-PD-1 antibody plus chemoradiotherapy in locally advanced esophageal squamous cancer, in the Journal: (JOURNAL) of 30/06/2022
- what: Given this background, the study was designed to evaluate the safety and antitumor activity of the initial therapy with anti-PD-1 plus CRT, which is the most widely used treatment in China for locally advanced ESCC.
- how: The results showed that the incidence of AEs was not statistically significant . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.